Biogen Idec's Profit Surges

Biogen Idec said robust sales of its multiple-sclerosis treatments Tecfidera and Tysabri helped drive up its earnings by 46% in the second quarter.



from WSJ.com: US Business http://ift.tt/WC5Qub

via IFTTT